Fed Circ denies bid to reverse favourable J&J ruling

The US Court of Appeals for the Federal Circuit has affirmed two Patent Trial and Appeal Board (PTAB) rulings that a Johnson & Johnson (J&J) subsidiary’s patent is valid and infringed.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

J&J units launch prostate cancer drug suit

31 May 2022 Johnson & Johnson subsidiaries Aragon Pharmaceuticals and Janssen Biotech have sued three pharma companies for alleged infringement of five patents relating to prostate cancer treatment Erleada.

Medtech

Fed Circuit revives bid to invalidate robotic surgery patent

3 May 2022 The US Court of Appeals for the Federal Circuit has renewed Auris Health’s attempt to invalidate Intuitive Surgical’s patent covering a robotic surgical tool.

Americas

J&J secures injunction against medical device counterfeiter

7 December 2021 Johnson & Johnson’s subsidiary Ethicon has obtained a permanent injunction against counterfeiters selling fake versions of Surgicel, an absorbable haemostat used to control bleeding during surgery.

More features

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation (Part I): Follow the money

Buchalter brings in new partner to head up medtech

Trump’s march-in rights threat: Why pharma is rethinking collaborations

UK gets new IP minister following cabinet reshuffle

Barnes & Thornburg reveals five new IP leaders

Fed Circ denies bid to reverse favourable J&J ruling

More on this story

Editor's picks

Editor's picks

More features